GRIA3 and frontotemporal dementia: Taking into consideration that the commercial autoantibodies and the sera from patients suffering from FTD were tested in the same experimental paradigm, the most conservative hypothesis to account for the inconsistency in the results is that the serum might contain components other than the GluA3 antibody that could influence the stability of the anti-GluA3/AMPA receptor interaction, shifting the outcome from facilitation to inhibition.